Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity

Virology

Volumn 439, Issue 1, 2013, Pages 34-41

  Durbin, Anna P ^a   Mayer, Sandra V ^b,c   Rossi, Shannan L ^b,c   Amaya Larios, Irma Y ^d   Ramos Castaneda, Jose ^d   Eong Ooi, Eng ^e   Jane Cardosa, M ^f   Munoz Jordan, Jorge L ^g   Tesh, Robert B ^b,c   Messer, William B ^h   Weaver, Scott C ^b,c   Vasilakis, Nikos ^b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f UNIVERSITI MALAYSIA SARAWAK   (Malaysia)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (Puerto Rico)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antigenic relationships; Dengue virus (DENV); Human DENV; Plaque reduction neutralization test (PRNT); Sylvatic DENV; Vaccine

Indexed keywords

DENGUE VACCINE;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; FEMALE; HUMAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCHOOL CHILD; URBAN AREA; VACCINATION; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AFRICA, WESTERN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ASIA, SOUTHEASTERN; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; URBAN POPULATION; YOUNG ADULT;

DENGUE VIRUS; DENGUE VIRUS GROUP; DENGUE VIRUS TYPE 4;

EID: 84874959601     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.01.018     Document Type: Article

References (70)

1. Barban V., Munoz-Jordan J.L., Santiago G.A., Mantel N., Girerd Y., Gulia S., Claude J.B., Lang J. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology 2012, 429:91-98.
2. Calisher C.H., Karabatsos N., Dalrymple J.M., Shope R.E., Porterfield J.S., Westaway E.G., Brandt W.E. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J. Gen. Virol. 1989, 70:37-43. Pt 1.
3. Cardosa J., Ooi M.H., Tio P.H., Perera D., Holmes E.C., Bibi K., Abdul Manap Z. Dengue virus serotype 2 from a sylvatic lineage isolated from a patient with dengue hemorrhagic fever. PLoS Negl.Trop. Dis. 2009, 3:e423.
4. Carey D.E., Causey O.R., Reddy S., Cooke A.R. Dengue viruses from febrile patients in Nigeria, 1964-68. Lancet 1971, 1:105-106.
5. Chen R., Vasilakis N. Dengue-Quo tu et quo vadis?. Viruses 2011, 3:1562-1608.
6. Clark D.V., Mammen M.P., Nisalak A., Puthimethee V., Endy T.P. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am. J. Trop. Med. Hyg. 2005, 72:786-791.
7. Cockburn J.J., Navarro Sanchez M.E., Fretes N., Urvoas A., Staropoli I., Kikuti C.M., Coffey L.L., Arenzana Seisdedos F., Bedouelle H., Rey F.A. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 2012, 20:303-314.
8. Cordellier R., Bouchite B., Roche J.C., Monteny N., Diaco B., Akoliba P. Circulation selvatique du virus Dengue 2, en 1980, dans les savanes sub-soudaniennes de Cote d'Ivoire. Cah. ORSTOM. ser Ent. Med. et Parasitol 1983, 21:165-179.
9. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 2001, 75:7769-7773.
10. de Alwis R., Smith S.A., Olivarez N.P., Messer W.B., Huynh J.P., Wahala W.M., White L.J., Diamond M.S., Baric R.S., Crowe J.E., de Silva A.M. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. PNAS 2012, 109:7439-7444.
11. Diallo M., Ba Y., Faye O., Soumare M.L., Dia I., Sall A.A. Vector competence of Aedes aegypti populations from Senegal for sylvatic and epidemic dengue 2 virus isolated in West Africa. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:493-498.
12. Diallo M., Ba Y., Sall A.A., Diop O.M., Ndione J.A., Mondo M., Girault L., Mathiot C. Amplification of the sylvatic cycle of dengue virus type 2, Senegal, 1999-2000: entomologic findings and epidemiologic considerations. Emerg. Infect. Dis. 2003, 9:362-367.
13. Diallo M., Sall A.A., Moncayo A.C., Ba Y., Fernandez Z., Ortiz D., Coffey L.L., Mathiot C., Tesh R.B., Weaver S.C. Potential role of sylvatic and domestic african mosquito species in dengue emergence. Am. J. Trop. Med. Hyg. 2005, 73:445-449.
14. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., Thumar B., Men R., Lai C.J., Elkins W.R., Chanock R.M., Murphy B.R., Whitehead S.S. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am. J. Trop. Med. Hyg. 2001, 65:405-413.
15. Durbin A.P., Kirkpatrick B.D., Pierce K.K., Schmidt A.C., Whitehead S.S. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011, 29:7242-7250.
16. Durbin A.P., McArthur J., Marron J.A., Blaney J.E., Thumar B., Wanionek K., Murphy B.R., Whitehead S.S. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccines 2006, 2:167-173.
17. Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., Rothman A.L., Libraty D.H. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 2004, 189:990-1000.
18. Fagbami A.H., Monath T.P., Fabiyi A. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. Trans. R. Soc. Trop. Med. Hyg. 1977, 71:60-65.
19. Falconar A.K., de Plata E., Romero-Vivas C.M. Altered enzyme-linked immunosorbent assay immunoglobulin M (IgM)/IgG optical density ratios can correctly classify all primary or secondary dengue virus infections 1 day after the onset of symptoms, when all of the viruses can be isolated. Clin. Vaccine Immunol. 2006, 13:1044-1051.
20. Fox A., Le N.M., Simmons C.P., Wolbers M., Wertheim H.F., Pham T.K., Tran T.H., Trinh T.M., Nguyen T.L., Nguyen V.T., Nguyen D.H., Farrar J., Horby P., Taylor W.R., Nguyen V.K. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl.Trop. Dis. 2011, 5:e967.
21. Franco, L., Palacios, G., Martinez, J.A., Vázquez, A., Savji, N., De Ory, F., Sanchez-Seco, M.P., Martín, D., Lipkin, W.I., Tenorio, A., 2011. First report of sylvatic DENV-2-associated dengue hemorrhagic fever in West Africa. PLos Negl. Trop. Dis. 5, e1251.
22. Guilarde A.O., Turchi M.D., Feres J.B., Rocha V.C., Levi B., Souza J.E., Boas V.A., Pannuti L.S., Martelli, C.M.C.S. Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. J. Infect. Dis. 2008, 197:817-824.
23. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., Yoksan S., Duan X., Ermak T.H., Kanesa-Thasan N., Bedford P., Lang J., Quentin-Millet M.J., Monath T.P. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccine 2006, 2:60-67.
24. Halstead S.B. Etiologies of the experimental dengues of Siler and Simmons. Am. J. Trop. Med. Hyg. 1974, 23:974-982.
25. Halstead S.B., Rojanasuphot S., Sangkawibha N. Original antigenic sin in dengue. Am. J. Trop. Med. Hyg. 1983, 32:154-156.
26. Hanafusa S., Chanyasanha C., Sujirarat D., Khuankhunsathid I., Yaguchi A., Suzuki T. Clinical features and differences between child and adult dengue infections in Rayong Province, southeast Thailand. Southeast Asian J. Trop. Med. Publ. Health 2008, 39:252-259.
27. Hanley K.A., Manlucu L.R., Manipon G.G., Hanson C.T., Whitehead S.S., Murphy B.R., Blaney J.E. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 2004, 22:3440-3448.
28. Hervy J.P., Legros F., Roche J.C., Monteny N., Diaco B. Circulation du dengue 2 dans plusieurs milieux boises des savanes soudaniennes de la region de Bobo-Dioulasso (Burkina Faso). Considerations entomologiques et epidemiologiques. Cah. ORSTOM. ser Ent. Med. et Parasitol 1984, 22:135-143.
29. Kaufman B.M., Summers P.L., Dubois D.R., Cohen W.H., Gentry M.K., Timchak R.L., Burke D.S., Eckels K.H. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1989, 41:576-580.
30. Kaufman B.M., Summers P.L., Dubois D.R., Eckels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 1987, 36:427-434.
31. Koh B.K., Ng L.C., Kita Y., Tang C.S., Ang L.W., Wong K.Y., James L., Goh K.T. The 2005 dengue epidemic in Singapore: epidemiology, prevention and control. Ann. Acad. Med. Singapore 2008, 37:538-545.
32. Kuno G., Gubler D.J., Oliver A. Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections. Trans. R. Soc. Trop. Med. Hyg. 1993, 87:103-105.
33. Kyle J.L., Harris E. Global spread and persistence of dengue. Annu. Rev. Microbiol. 2008, 62:71-92.
34. Lanata C.F., Andrade T., Gil A.I., Terrones C., Valladolil O., Zambrano B., Saville M., Crevat D. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30:5935-5941.
35. Low J.G., Ooi E.E., Tolfvenstam T., Leo Y.S., Hibberd M.L., Ng L.C., Lai Y.L., Yap G.S., Li C.S., Vasudevan S.G., Ong A. Early dengue infection and outcome study (EDEN)-study design and preliminary findings. Ann. Acad. Med. Singapore 2006, 35:783-789.
36. Mathers C.D., Ezzati M., Lopez A.D. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl.Trop. Dis. 2007, 1:e114.
37. McArthur J.H., Durbin A.P., Marron J.A., Wanionek K.A., Thumar B., Pierro D.J., Schmidt A.C., Blaney J.E., Murphy B.R., Whitehead S.S. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am. J. Trop. Med. Hyg. 2008, 79:678-684.
38. Monlun E., Zeller H., Traore-Lamizana M., Hervy J.P., Adam F., Mondo M., Digoutte J.P. Caracteres cliniques et epidemiologiques de la dengue 2 au Senegal. Med. Mal. Infect. 1992, 22:718-721.
39. Okuno Y., Fukunaga T., Tadano M., Fukai K., Ikeda T., Sekii K., Ariyoshi H. Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943. Biken J. 1983, 26:161-163.
40. Papaevangelou G., Halstead S.B. Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic?. J. Trop. Med. Hyg. 1977, 80:46-51.
41. Pengsaa K., Luxemburger C., Sabchareon A., Limkittikul K., Yoksan S., Chambonneau L., Chaovarind U., Sirivichayakul C., Lapphra K., Chanthavanich P., Lang J. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J. Infect. Dis. 2006, 194:1570-1576.
42. Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990, 174:479-493.
43. Robin Y., Cornet M., Heme G., Le Gonidec G. Isolement du virus dela dengue au Senegal. Ann. Virol. (Inst. Pasteur) 1980, 131:149-154.
44. Roche J.C., Cordellier R., Hervy J.P., Digoutte J.P., Monteny N. Isolement de 96 souches de virus dengue 2 a partir de moustiques captures en Cote d'Ivoire et en Haute Volta. Ann. Virol. (Inst. Pasteur) 1983, 134E:233-244.
45. Roehrig J.T., Bolin R.A., Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246:317-328.
46. Rosen L. The pathogenesis of dengue haemorrhagic fever. A critical appraisal of current hypotheses. S. Afr. Med. J. Suppl. 1986, 40-42.
47. Rudnick A. Studies of the ecology of dengue in Malaysia: a preliminary report. J. Med. Entomol. 1965, 2:203-208.
48. Rudnick A. Ecology of dengue virus. Asian J. Infect. Dis. 1978, 2:156-160.
49. Rudnick A. The ecology of the dengue virus complex in peninsular Malaysia. Proceedings of the International Conference on dengue/DHF 1984, University of Malaysia Press, Kuala Lampur, Malaysia. T. Pang, R. Pathmanatan (Eds.).
50. Rudnick A. Dengue virus ecology in Malaysia. Inst. Med. Res. Malays. Bull. 1986, 23:51-152.
51. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., Jiwariyavej V., Dulyachai W., Pengsaa K., AnhWartel T., Moureau A., Saville M., Bouckenooghe A., Viviani S., Tornieporth N.G., Lang J. Protective effi cacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 1-9.
52. Sabin A.B. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1952, 1:30-50.
53. Saluzzo J.F., Cornet M., Castagnet P., Rey C., Digoutte J.P. Isolation of dengue 2 and dengue 4 viruses from patients in Senegal. Trans. R. Soc. Trop. Med. Hyg. 1986, 80:5.
54. Schlesinger J.J., Brandriss M.W., Cropp C.B., Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 1986, 60:1153-1155.
55. Siqueira J.B., Martelli C.M., Coelho G.E., Simplicio A.C., Hatch D.L. Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerg. Infect. Dis. 2005, 11:48-53.
56. Smith C.E. The history of dengue in tropical Asia and its probable relationship to the mosquito Aedes aegypti. J. Trop. Med. Hyg. 1956, 59:243-251.
57. Smith C.E. The distribution of antibodies to Japanese Encephalitis, dengue, and yellow fever viruses in five rural communities in Malaya. Trans. R. Soc. Trop. Med. Hyg. 1958, 52:237-252.
58. Tadano M., Okuno Y., Fukunaga T., Fukai K. Retrospective serological studies on dengue epidemics in Osaka and Okinawa. Biken J. 1983, 26:165-167.
59. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739.
60. Twiddy S.S., Holmes E.C., Rambaut A. Inferring the rate and time-scale of dengue virus evolution. Mol. Biol. Evol. 2003, 20:122-129.
61. Vasilakis N., Durbin A., Travassos da Rosa A.P.A., Munoz-Jordan J.L., Tesh R.B., Weaver S.C. Antigenic relationships between sylvatic and endemic dengue viruses. Am. J. Trop. Med. Hyg. 2008, 79:128-132.
62. Vasilakis N., Fokam E.B., Hanson C.T., Weinberg E., Sall A.A., Whitehead S.S., Hanley K.A., Weaver S.C. Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains. Virology 2008, 377:296-307.
63. Vasilakis N., Shell E.J., Fokam E.B., Mason P.W., Hanley K.A., Estes D.M., Weaver S.C. Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology 2007, 358:402-412.
64. Vasilakis N., Tesh R.B., Weaver S.C. Sylvatic dengue virus type 2 activity in humans, Nigeria, 1966. Emerg. Infect. Dis. 2008, 14:502-504.
65. Vasilakis N., Cardosa M.J., Hanley K.A., Holmes E.C., Weaver S.C. The fever from the forest: prospects for continued emergence of sylvatic dengue virus and impact on public health. Nature Rev. Microbiol. 2011, 9:532-541.
66. Wahala W.M., Donaldson E.F., de Alwis R., Accavitti-Loper M.A., Baric R.S., de Silva A.M. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 2010, 6:e1000821.
67. Wang E., Ni H., Xu R., Barrett A.D., Watowich S.J., Gubler D.J., Weaver S.C. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J. Virol. 2000, 74:3227-3234.
68. Wichmann O., Hongsiriwon S., Bowonwatanuwong C., Chotivanich K., Sukthana Y., Pukrittayakamee S. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop. Med. Int. Health 2004, 9:1022-1029.
69. Witayathawornwong P. DHF in infants, late infants and older children: a comparative study. Southeast Asian J. Trop. Med. Publ. Health 2005, 36:896-900.
70. Zulueta A., Martin J., Hermida L., Alvarez M., Valdes I., Prado I., Chinea G., Rosario D., Guillen G., Guzman M.G. Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 2006, 121:65-73.